Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols

• Status: Unknown status
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will study 2 doses of etoricoxib to prove that 60 mg once daily will be non-inferior to etoricoxib 90mg daily (for 14 days) in the treatment of acute ankle sprain in sports. The investigators objective is to discuss the point that the investigators will follow the minimal dose that is effective for the treatment of this acute condition in orthopedic.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Núcleo de Estudos em Esportes e Ortopedia, Brazil
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Anti-Inflammatory Agents, Non-Steroidal; Etoricoxib

Criteria

Inclusion Criteria:

• patients that suffered an ankle sprain in the last 12 hours and seek medical assistance

Exclusion Criteria:

• anterior history of trauma / fractures in the affected ankle

• history of hypertension / gastrointestinal problems

• patients that did not agree to sign the informed consent to participate in the study